Phase I clinical trial - Pédiatrie Tumeurs solides

I3Y-MC-JPCS
Pédiatrie Tumeurs solides
Ouvert depuis le: 09.19.2021
Site: Paris
Public cible
Enfant
Adulte
JPCS(2.1) Clinical Protocol Addendum Page 1;LY2835219;1. Protocol Addendum I3Y-MC-JPCS(2.1);A Phase 1b Dose Escalation Study of Abemaciclib in;Combination with Temozolomide and Irinotecan (Part A);and Abemaciclib in Combination with Temozolomide;(Part B) in Pediatric and Young Adult Patients with;Relapsed/Refractory Solid Tumors
Description de l'essai

The study's purpose is to see if the drug abemaciclib is safe and effective in combination with temozolomide and irinotecan (Part A) and abemaciclib in combination with temozolomide (Part B) in pediatric and young adult participants with relapsed/refractory solid tumors.